ArticleAnnals of neurology2026

Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".

Gabriel Cerono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.